Chipiron, a Paris-based deeptech startup, has successfully raised $17M in a Series A funding round to enhance its innovative MRI technologies designed to detect cancer early. The company has built a substantial funding history since its inception in 2020, accumulating over $22M through various investment rounds and public support. Key investors included Blast, EIC Fund, and iXcore, who recognize the potential of Chipiron's technology to significantly improve public health outcomes by making MRI accessible to a broader audience.
Chipiron is exactly the kind of biotech we want to boost at Blast. They're making possible what traditional medicine still struggles to do: detect life-threatening diseases early.
iXcore chose to invest in Chipiron for three reasons: the team is outstanding, the science and technology behind this MRI are perfectly mastered, and the company is clearly offering a game-changing product.
The EIC Fund mentions that its investment in Chipiron aligns with its mission to back European deeptech, particularly when it involves a major technological advancement in a key sector.
Collection
[
|
...
]